MCP-1 and soluble TWEAK levels are independently associated with coronary artery disease severity in patients with chronic kidney disease. (14th September 2015)

• Record Type: Journal Article
• Authors: Akdoğan, Mehmet Fatih; Azak, Alper; Denizli, Nazım; Huddam, Bülent; Koçak, Gülay; Gücün, Murat; Tatlısu, Mustafa Adem; Demirci, Recep; Yılmaz, Bilal; Dikeç, Mehmet; Bakırtaş, Murat; Akdağ, İbrahim; Duranay, Murat
• Is Part Of: Renal failure. Volume 37:Number 8(2015)
• Page Start: 1297
• Page End: 1302
• Publication Date: 2015-09-14
• Subjects: Chronic kidney disease -- coronary arterial disease -- Gensini score -- MCP-1 -- TWEAK; Chronic renal failure -- Periodicals; Acute renal failure -- Periodicals; Uremia -- Periodicals; 616.614005
• DOI: 10.3109/0886022X.2015.1065428
• Languages: English
• ISSNs: 0886-022X

Abstract

Abstract: Purpose : Patients diagnosed with chronic kidney disease (CKD) have a greater rate of cardiovascular mortality when compared with the general population. The soluble form of TNF-like weak inducer of apoptosis (TWEAK) and monocyte chemoattractan protein 1 (MCP-1) play important roles in cellular proliferation, migration and apoptosis. The current study aimed to analyze whether soluble TWEAK (sTWEAK) and MCP-1 levels are associated with the severity of coronary arterial disease (CAD) in CKD patients. Methods : Ninety-seven patients diagnosed with CKD stages 2–3 according to their estimated glomerular filtration rate and the presence of kidney injury were included in the study. Plasma sTWEAK and MCP-1 concentrations were determined using commercially available ELISA kits. Coronary angiographies were performed through femoral artery access using the Judkins technique. Results : Correlation analysis of sTWEAK and Gensini scores showed significant association ( p < 0.01, r 2 = 0.287). Also significant correlation has been found in MCP-1 levels and Gensini scores ( p < 0.01, r 2 = 0.414). When patients were divided into two groups with a limit of 17 according to their Gensini score, sTWEAK levels indicated a statistically significant difference ( p < 0.01). Conclusions : Our findings support a relationship between sTWEAK and MCP-1 levels and CAD in CKD stages 2–3 patients.